Sign In
Buy ARNA
$99.99
+0 (+0%)
At Close: May 27, 2022
Advisors Asset Management Inc. Sells 2,202 Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
08:20am, Wednesday, 01'st Apr 2020
Advisors Asset Management Inc. lowered its position in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 8.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securiti
Arena Pharmaceuticals Announces Topline Data For New Development Program
12:00am, Wednesday, 01'st Apr 2020's Top Upgrades, Downgrades For March 31, 2020
01:34pm, Tuesday, 31'st Mar 2020
Upgrades
For Ultrapar Participacoes SA (NYSE: UGP), B of A Securities upgraded the stock from Neutral to Buy. For the fourth quarter, Ultrapar Participacoes had an EPS...
Tuesday's top analyst upgrades and downgrades included Apache, Broadcom, Caterpillar, Dollar General, Microsoft, NXP Semiconductors, Salesforce.com, Sirius XM, Slack and Yelp.
Mizuho sees 86% upside in Sarepta in premarket analyst action
11:18am, Tuesday, 31'st Mar 2020
Apellis Pharmaceuticals (NASDAQ:APLS) initiated with an Outperform rating and a $54 (88% upside) price target at BMO.Arena Pharmaceuticals (NASDAQ:ARNA) initiated with a Buy rating and a $95 (126% ups
Arena Pharmaceuticals initiated with a Buy at Guggenheim ARNA
10:37am, Tuesday, 31'st Mar 2020
Arena Pharmaceuticals initiated with a Buy at Guggenheim Guggenheim ARNA
Arena Pharmaceuticals (NASDAQ:ARNA) Trading Down 5.4%
07:52am, Tuesday, 31'st Mar 2020
Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) traded down 5.4% on Monday . The company traded as low as $41.32 and last traded at $42.12, 527,329 shares were traded during trading. A decline of
Guggenheim Securities Initiates Coverage On Arena Pharmaceuticals with Buy Rating, Announces Price Target to $95
12:00am, Tuesday, 31'st Mar 2020Arena Pharmaceuticals Names James C. Mullen as an Independent Senior Advisor
12:30pm, Monday, 30'th Mar 2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that James C. Mullen has agreed to serve as an independent senior advisor to the Company.
Arena Pharmaceuticals (NASDAQ:ARNA) Upgraded to "Buy" at Bank of America
10:00am, Monday, 30'th Mar 2020
Bank of America upgraded shares of Arena Pharmaceuticals (NASDAQ:ARNA) from a neutral rating to a buy rating in a report published on Thursday, Briefing.com Automated Import reports. The firm currentl
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Stake Raised by Alliancebernstein L.P.
09:28am, Monday, 30'th Mar 2020
Alliancebernstein L.P. increased its holdings in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 4.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Ex
Stock Upgrades: Arena Pharmaceuticals Shows Rising Relative Strength
12:00am, Monday, 30'th Mar 2020Great West Life Assurance Co. Can Takes $150,000 Position in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
11:13am, Sunday, 29'th Mar 2020
Great West Life Assurance Co. Can acquired a new position in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commis
Axa Increases Stock Position in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
09:28am, Sunday, 29'th Mar 2020
Axa boosted its stake in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 2.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). Th
